Phase Ii study of recombinant interferon-gamma in patients with disseminated malignant melanoma
Creagan, E.T.; Ahmann, D.L.; Long, H.J.; Frytak, S.; Sherwin, S.A.; Chang, M.N.
Cancer Treatment Reports 71(9): 843-844
1987
ISSN/ISBN: 0361-5960 PMID: 3113730 Document Number: 291046
Twenty-eight patients with disseminated malignant melanoma received daily im therapy with recombinant interferon-gamma. The dose was 0.25 mg/m2 on Days 1-7 followed by a daily dose of 0.5 mg/m2 if tolerated. Among 27 patients, we observed three objective partial regressions (8.3, 3.7, and 3.9+ months). The median leukocyte count nadir was 2.5 X 10(3)/mm3 (range, 1.4-5.1). Constitutional symptoms included moderate to severe fever greater than 37 degrees C (100%), fatigue (59%), chills (37%), and mild to moderate myalgias (64%). Recombinant interferon-gamma produces manageable side effects but limited efficacy as employed in this study.